Contact
searchSearch
HMP Global
Login

Oncology

Featured

Estelamari Rodriguez, MD
Videos
Perioperative Immunotherapy for Patients With Resectable Non-Small Cell Lung Cancer
03/15/2026
Estelamari Rodriguez, MD, MPH
Estelamari Rodriguez, MD, discusses the importance of continuing immunotherapy after surgery to maintain immune activation and reduce recurrence risk in patients with early-stage resectable non-small cell lung cancer.
Estelamari Rodriguez, MD, discusses the importance of continuing immunotherapy after surgery to maintain immune activation and reduce recurrence risk in patients with early-stage resectable non-small cell lung cancer.
Estelamari Rodriguez, MD,...
03/15/2026
Oncology
Joshua Linscott, MD
Videos
Consolidation Therapy After Clinical Complete Response in Muscle-Invasive Bladder Cancer
03/15/2026
Joshua Linscott, MD, PhD, discusses the role of consolidation therapy in muscle-invasive bladder cancer after a clinical complete response to chemotherapy.
Joshua Linscott, MD, PhD, discusses the role of consolidation therapy in muscle-invasive bladder cancer after a clinical complete response to chemotherapy.
Joshua Linscott, MD, PhD,...
03/15/2026
Oncology
Kelsey Pan, MD
Videos
Defining the Optimal Immunotherapy Strategy in Resectable Non-Small Cell Lung Cancer
03/14/2026
Kelsey Pan, MD, discusses whether a neoadjuvant-only immunotherapy approach may be sufficient for patients with resectable non-small cell lung cancer.
Kelsey Pan, MD, discusses whether a neoadjuvant-only immunotherapy approach may be sufficient for patients with resectable non-small cell lung cancer.
Kelsey Pan, MD, discusses...
03/14/2026
Oncology
Luis Raez, MD
Videos
Second-Line Treatment Options in Metastatic NSCLC
03/14/2026
Luis Raez, MD
Luis Raez, MD, discusses current second-line treatment options for metastatic non-small cell lung cancer without actionable mutations after progression on chemoimmunotherapy.
Luis Raez, MD, discusses current second-line treatment options for metastatic non-small cell lung cancer without actionable mutations after progression on chemoimmunotherapy.
Luis Raez, MD, discusses current...
03/14/2026
Oncology
Tian Zhang, MD
Videos
Optimizing First-Line Immunotherapy in Metastatic Renal Cell Carcinoma
03/14/2026
Tian Zhang, MD, discusses optimal front-line immunotherapy strategies for patients with metastatic renal cell carcinoma.
Tian Zhang, MD, discusses optimal front-line immunotherapy strategies for patients with metastatic renal cell carcinoma.
Tian Zhang, MD, discusses...
03/14/2026
Oncology
Guru Sonpavde, MD
Videos
ctDNA Guided Adjuvant Therapy for Patients With Muscle-Invasive Bladder Cancer
03/14/2026
Guru Sonpavde, MD, discusses whether ctDNA-guided adjuvant therapy should be used in patients with high-risk muscle-invasive bladder cancer.
Guru Sonpavde, MD, discusses whether ctDNA-guided adjuvant therapy should be used in patients with high-risk muscle-invasive bladder cancer.
Guru Sonpavde, MD, discusses...
03/14/2026
Oncology
Melinda Telli, MD
Videos
Immunotherapy for All Patients With Triple-Negative Breast Cancer
03/14/2026
Melinda Telli, MD, discusses whether immune checkpoint inhibitor therapy should be used for all patients with early-stage triple-negative breast cancer.
Melinda Telli, MD, discusses whether immune checkpoint inhibitor therapy should be used for all patients with early-stage triple-negative breast cancer.
Melinda Telli, MD, discusses...
03/14/2026
Oncology
Christopher Hourigan, MD, PhD
Videos
The Expanding Role of Minimal Residual Disease Testing in Acute Myeloid Leukemia
03/13/2026
Christopher Hourigan, DM, DPhil, FRCP
Christopher Hourigan, MD, PhD, reviews the most recent high-impact developments in measurable residual disease (MRD) testing in acute myeloid leukemia, focusing on key updates from recent months.
Christopher Hourigan, MD, PhD, reviews the most recent high-impact developments in measurable residual disease (MRD) testing in acute myeloid leukemia, focusing on key updates from recent months.
Christopher Hourigan, MD, PhD,...
03/13/2026
Oncology
Nina Wagner-Johnston, MD
Videos
Advances in Follicular Lymphoma: Long-Term Outcomes, CAR-T Durability, and Emerging Treatment Strategies
03/13/2026
Nina Wagner Johnston, MD
Nina Wagner-Johnston, MD, highlights excellent long-term outcomes in follicular lymphoma, including 18-year survival data from the University of Iowa/Mayo Clinic SPORE resource, durable CAR-T responses, and promising frontline and relapsed...
Nina Wagner-Johnston, MD, highlights excellent long-term outcomes in follicular lymphoma, including 18-year survival data from the University of Iowa/Mayo Clinic SPORE resource, durable CAR-T responses, and promising frontline and relapsed...
Nina Wagner-Johnston, MD,...
03/13/2026
Oncology
Holly Stewart, PA-C
Videos
Managing Emotional Care Challenges in Cancer Treatment
03/12/2026
Holly Stewart, PA-C, presents a discussion on tips and strategies for navigating emotional care challenges across the cancer journey, including monitoring moods and habits and utilizing the SPIKES protocol.
Holly Stewart, PA-C, presents a discussion on tips and strategies for navigating emotional care challenges across the cancer journey, including monitoring moods and habits and utilizing the SPIKES protocol.
Holly Stewart, PA-C, presents a...
03/12/2026
Oncology Learning Network APP Institute
From Oncology Learning Network APP Institute
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology

Videos

Estelamari Rodriguez, MD
Videos
Perioperative Immunotherapy for Patients With Resectable Non-Small Cell Lung Cancer
03/15/2026
Estelamari Rodriguez, MD, MPH
Estelamari Rodriguez, MD, discusses the importance of continuing immunotherapy after surgery to maintain immune activation and reduce recurrence risk in patients with early-stage resectable non-small cell lung cancer.
Estelamari Rodriguez, MD, discusses the importance of continuing immunotherapy after surgery to maintain immune activation and reduce recurrence risk in patients with early-stage resectable non-small cell lung cancer.
Estelamari Rodriguez, MD,...
03/15/2026
Oncology
Joshua Linscott, MD
Videos
Consolidation Therapy After Clinical Complete Response in Muscle-Invasive Bladder Cancer
03/15/2026
Joshua Linscott, MD, PhD, discusses the role of consolidation therapy in muscle-invasive bladder cancer after a clinical complete response to chemotherapy.
Joshua Linscott, MD, PhD, discusses the role of consolidation therapy in muscle-invasive bladder cancer after a clinical complete response to chemotherapy.
Joshua Linscott, MD, PhD,...
03/15/2026
Oncology
Kelsey Pan, MD
Videos
Defining the Optimal Immunotherapy Strategy in Resectable Non-Small Cell Lung Cancer
03/14/2026
Kelsey Pan, MD, discusses whether a neoadjuvant-only immunotherapy approach may be sufficient for patients with resectable non-small cell lung cancer.
Kelsey Pan, MD, discusses whether a neoadjuvant-only immunotherapy approach may be sufficient for patients with resectable non-small cell lung cancer.
Kelsey Pan, MD, discusses...
03/14/2026
Oncology
Luis Raez, MD
Videos
Second-Line Treatment Options in Metastatic NSCLC
03/14/2026
Luis Raez, MD
Luis Raez, MD, discusses current second-line treatment options for metastatic non-small cell lung cancer without actionable mutations after progression on chemoimmunotherapy.
Luis Raez, MD, discusses current second-line treatment options for metastatic non-small cell lung cancer without actionable mutations after progression on chemoimmunotherapy.
Luis Raez, MD, discusses current...
03/14/2026
Oncology
Tian Zhang, MD
Videos
Optimizing First-Line Immunotherapy in Metastatic Renal Cell Carcinoma
03/14/2026
Tian Zhang, MD, discusses optimal front-line immunotherapy strategies for patients with metastatic renal cell carcinoma.
Tian Zhang, MD, discusses optimal front-line immunotherapy strategies for patients with metastatic renal cell carcinoma.
Tian Zhang, MD, discusses...
03/14/2026
Oncology
Guru Sonpavde, MD
Videos
ctDNA Guided Adjuvant Therapy for Patients With Muscle-Invasive Bladder Cancer
03/14/2026
Guru Sonpavde, MD, discusses whether ctDNA-guided adjuvant therapy should be used in patients with high-risk muscle-invasive bladder cancer.
Guru Sonpavde, MD, discusses whether ctDNA-guided adjuvant therapy should be used in patients with high-risk muscle-invasive bladder cancer.
Guru Sonpavde, MD, discusses...
03/14/2026
Oncology
Melinda Telli, MD
Videos
Immunotherapy for All Patients With Triple-Negative Breast Cancer
03/14/2026
Melinda Telli, MD, discusses whether immune checkpoint inhibitor therapy should be used for all patients with early-stage triple-negative breast cancer.
Melinda Telli, MD, discusses whether immune checkpoint inhibitor therapy should be used for all patients with early-stage triple-negative breast cancer.
Melinda Telli, MD, discusses...
03/14/2026
Oncology
Christopher Hourigan, MD, PhD
Videos
The Expanding Role of Minimal Residual Disease Testing in Acute Myeloid Leukemia
03/13/2026
Christopher Hourigan, DM, DPhil, FRCP
Christopher Hourigan, MD, PhD, reviews the most recent high-impact developments in measurable residual disease (MRD) testing in acute myeloid leukemia, focusing on key updates from recent months.
Christopher Hourigan, MD, PhD, reviews the most recent high-impact developments in measurable residual disease (MRD) testing in acute myeloid leukemia, focusing on key updates from recent months.
Christopher Hourigan, MD, PhD,...
03/13/2026
Oncology
Nina Wagner-Johnston, MD
Videos
Advances in Follicular Lymphoma: Long-Term Outcomes, CAR-T Durability, and Emerging Treatment Strategies
03/13/2026
Nina Wagner Johnston, MD
Nina Wagner-Johnston, MD, highlights excellent long-term outcomes in follicular lymphoma, including 18-year survival data from the University of Iowa/Mayo Clinic SPORE resource, durable CAR-T responses, and promising frontline and relapsed...
Nina Wagner-Johnston, MD, highlights excellent long-term outcomes in follicular lymphoma, including 18-year survival data from the University of Iowa/Mayo Clinic SPORE resource, durable CAR-T responses, and promising frontline and relapsed...
Nina Wagner-Johnston, MD,...
03/13/2026
Oncology
Holly Stewart, PA-C
Videos
Managing Emotional Care Challenges in Cancer Treatment
03/12/2026
Holly Stewart, PA-C, presents a discussion on tips and strategies for navigating emotional care challenges across the cancer journey, including monitoring moods and habits and utilizing the SPIKES protocol.
Holly Stewart, PA-C, presents a discussion on tips and strategies for navigating emotional care challenges across the cancer journey, including monitoring moods and habits and utilizing the SPIKES protocol.
Holly Stewart, PA-C, presents a...
03/12/2026
Oncology Learning Network APP Institute

Insights From the ASCO Annual Meeting

Raajit Rampal, MD, PhD
Conference Coverage
Pacritinib Therapy May Improve Hemoglobin Responses Among Patients With Myelofibrosis
09/03/2025
Raajit Rampal, MD, PhD
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares...
09/03/2025
Oncology
John Strickler, MD
Videos
Addition of FOLFIRI to Sotorsaib and Panitumumab Demonstrates Long-Term Efficacy, Safety Among Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer
08/21/2025
John Strickler, MD
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses...
08/21/2025
Oncology
Amer Zeidan, MBBS, MHS
Conference Coverage
Decitabine-Cedazuridine Plus Venetoclax Therapy Shows Efficacy and Safety for Patients With Newly Diagnosed AML
08/20/2025
Amer Zeidan, MBBS
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares...
08/20/2025
Oncology
Meghan Mooradian, MD
Conference Coverage
Neoadjuvant Dostarlimab Plus Cobolimab Demonstrates Promise Among Patients With High-Risk Resectable Melanoma
08/12/2025
Meghan Mooradian, MD
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses...
08/12/2025
Oncology
Nick James, MD, PhD
Conference Coverage
Use of a Multimodal Artificial Intelligence Algorithm in High-Risk Non-Metastatic Prostate Cancer
08/12/2025
Nicholas James, MD
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses...
08/12/2025
Oncology
Stephen Bagley, MD
Conference Coverage
Intracerebroventricular Delivery of CART-EGFR-IL13Rα2 Demonstrates Promise Among Patients With Recurrent Glioblastoma
08/05/2025
Stephen Bagley, MD
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses...
08/05/2025
Oncology
Zeynep Eroglu, MD
Conference Coverage
First-Line Encorafenib Plus Binimetinib and Nivolumab for Patients With BRAF-Mutated Melanoma Brain Metastases
07/24/2025
Zeynep Eroglu, MD
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses...
07/24/2025
Oncology
Herbert Loong, MD
Conference Coverage
BAY 2927088 Demonstrates Promise Among Patients With HER2-Mutated Non-Small Cell Lung Cancer
07/24/2025
Herbert Loong, MD
Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.
Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.
Herbert Loong, MD, discusses...
07/24/2025
Oncology
Georgina Long, MD, PhD
Conference Coverage
Addition of Relatimab to Nivolumab Did Not Significantly Improve Outcomes for Patients With Melanoma
07/24/2025
Georgina Long, MBBS, PhD
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD,...
07/24/2025
Oncology
Alexander van Akkooi, MD, PhD
Conference Coverage
Adjuvant Encorafenib Plus Binimetinib Demonstrates Promise Among Patients With BRAF-Mutated Melanoma
07/24/2025
Alexander Van Akkooi, MD, PhD
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD,...
07/24/2025
Oncology

Insights From the ESMO Congress

Stephen Freedland, MD
Videos
Enzalutamide Plus Androgen Deprivation Therapy in Biochemically Recurrent Prostate Cancer
12/02/2025
Stephen J. Freedland, MD
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses...
12/02/2025
Oncology
Brian Slomovitz, MD
Videos
Relacorilant Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
12/02/2025
Brian M. Slomovitz, MD, MS
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses...
12/02/2025
Oncology
Pasi Jänne, MD, PhD
Videos
Osimertinib Plus Chemotherapy Provides Broad Survival Benefit in EGFR-Mutant NSCLC
12/02/2025
Pasi Jänne, MD, PhD
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses...
12/02/2025
Oncology
David Goldstein, MD
Videos
Regorafenib Plus Nivolumab Fails to Improve Outcomes in Gastric or Gastroesophageal Cancer
12/02/2025
David Goldstein, MD
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses...
12/02/2025
Oncology
Sara Lonardi, MD
Videos
Dual Immunotherapy Delivers Durable Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
11/13/2025
Sara Lonardi, MD
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated...
11/13/2025
Oncology
Sanjay Popat, MD, PhD
Videos
First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC
11/13/2025
Sanjay Popat, MD
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses...
11/13/2025
Oncology
Janice Mehnert, MD
Videos
Pembrolizumab Lowers Distant Recurrence Risk in Resected Merkel Cell Carcinoma
11/10/2025
Janice Mehnert, MD
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses...
11/10/2025
Oncology
Nima Nabavizadeh, MD
Videos
MCED Blood Test Detects Cancer Early With High Accuracy
11/10/2025
Nima Nabavizadeh, MD
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses...
11/10/2025
Oncology
Maria De Santis, MD
Videos
Addition of Durvalumab Strengthens Treatment for Patients With High-Risk Non–Muscle Invasive Bladder Cancer
11/10/2025
Maria De Santis, MD
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses...
11/10/2025
Oncology
Dean Fennell, MD, PhD
Videos
Intratumor Heterogeneity Predicts Niraparib Benefit in Relapsed Mesothelioma
11/10/2025
Dean Fennell, MD, PhD
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses...
11/10/2025
Oncology

Live Meetings

Recent News

News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology
News
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
FDA Alerts
Ipsen Voluntarily Withdraws Tazemetostat Following Updated Safety Findings from the SYMPHONY-1 Trial
03/11/2026
Stephanie Holland
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data...
03/11/2026
Oncology
News
Pimicotinib Maintains Favorable Safety Profile in Tenosynovial Giant Cell Tumor
03/11/2026
Stephanie Holland
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the...
03/11/2026
Oncology
News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology
News
Real-World Analysis Evaluates Survival and Quality of Life Patterns of Third-Line Systemic Therapies for ES-SCLC
03/04/2026
Emily Estrada
Third-line systemic therapy was associated with limited survival benefit and stability, but did not show improved quality of life, in a real-world registry analysis of treatment patterns for patients with extensive-stage small cell lung...
Third-line systemic therapy was associated with limited survival benefit and stability, but did not show improved quality of life, in a real-world registry analysis of treatment patterns for patients with extensive-stage small cell lung...
Third-line systemic therapy was...
03/04/2026
Oncology
News
Sequential Thoracic Radiotherapy After Chemoimmunotherapy Associated With Improved Survival in ES-SCLC
03/04/2026
Emily Estrada
Among patients with extensive-stage small cell lung cancer responding to first-line chemoimmunotherapy, sequential thoracic radiotherapy was associated with improved progression-free and overall survival and fewer adverse events compared with...
Among patients with extensive-stage small cell lung cancer responding to first-line chemoimmunotherapy, sequential thoracic radiotherapy was associated with improved progression-free and overall survival and fewer adverse events compared with...
Among patients with...
03/04/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use